Abstract
As has been consistently demonstrated, rapid tests administered at regular intervals can offer significant benefits to both individuals and their communities at large by helping identify whether an individual is infected and potentially infectious. An additional advantage to the individual is that positive tests may be provided sufficiently early enough during their infection that treatment with antiviral treatments can effectively inhibit development of severe disease, particularly when PCR uptake is limited and delays to receipt of results are substantial. Here, we provide a quantitative illustration of the extent to which rapid tests administered at various intervals can deliver benefits accrued from the novel Pfizer treatment (Paxlovid). We find that strategies for which tests are administered more routinely, i.e. every other day or once every three days, are associated with greater reductions in the risk of hospitalization and correspondingly, higher proportions of the infected population benefiting from treatment. We further observed that reduced positive-test-to-treatment delays and increased treatment coverage have a critical influence on average treatment benefits, signaling the importance of treatment access.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All code is available at https://github.com/goshgondar2018/LFT_treatment_analysis
